Effect of sports rehabilitation nursing on improving daytime sleepiness of patients with Parkinson's disease

doi:10.3877/cma.j.issn.2095-8757.2021.01.004

Abstract

Abstract:

Objective

To observe the clinical efficacy of exercise rehabilitation nursing on daytime sleepiness in Parkinson's disease.

Methods

51 patients with Parkinson's disease with daytime sleepiness admitted to the Second People's Hospital of Lianyungang City from February 2017 to November 2019 were selected. Among them, 24 patients (intervention group) received 6 weeks of exercise rehabilitation nursing on the basis of routine standardized treatment for Parkinson's disease, and 27 patients (control group) received routine standardized treatment and nursing for Parkinson's disease. Before and after treatment, Epworth Sleepiness Scale (ESS), PD Sleep Scale (PDSS), Faintness Scale, Self-Rating Anxiety Scale, Self-Rating Depression Scale, and Daily Living Ability Scale were evaluated. The sleep time, sleep latency, times of sleep interruption after sleep, nocturnal sleep-wake time and four sleep indexes (sleep quality, wakefulness index after waking, easy waking and dreaming) scores of two groups were compared. The independent sample t test was used to compare the measurement data between groups, and the χ² test was used to compare the enumeration data. Repeated measure analysis of variance was used to compare continuous time point indicators between the two groups.

Results

After treatment, the ESS, PDSS scores, latency period, number of sleep interruptions and night sleep quality in the sleep log showed a significant grouping effect. The ESS and PDSS scores in the intervention group were significantly better than those in the control group (F=17.780, 23.400, P < 0.01). The incubation period of the intervention group was significantly shorter than that of the control group, the frequency of sleep interruption was significantly less than that of the control group, and the sleep quality of the intervention group was significantly better than that of the control group (F=12.390, 15.290, 50.730, P < 0.01). The FRAIL, SAS, SDS, ADL score, and sleep time, night sleep-wake time, wakefulness index after wakefulness, wakefulness and dream score had no grouping effect (F=18.460, 19.800, 13.730, 19.670, 0.890, 25.640, 16.870, 19.860, 16.480, P > 0.05).

Conclusion

Exercise rehabilitation nursing interventions can improve daytime sleepiness in Parkinson's disease, as well as shorten nocturnal sleep latency, reduce the number of nocturnal sleep interruptions, and improve nocturnal sleep quality.

Key words: Parkinson's disease, Exercise rehabilitation nursing, Excessive daytime sleepiness, Non-motor symptoms

Dandan Liu, Yan Chen, Juan LI, Xiaozhu Shen, Chen Gong, Min Li, Xueling Bai, Houqin Liu, Qian Zhang. Effect of sports rehabilitation nursing on improving daytime sleepiness of patients with Parkinson's disease[J]. Chinese Journal of Geriatrics Research(Electronic Edition), 2021, 08(01): 14-19.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlnbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-8757.2021.01.004

https://zhlnbyjdzzz.cma-cmc.com.cn/EN/Y2021/V08/I01/14

Figures/Tables 3

References 29

[1]	Takenoshita S, Nishino S. Pharmacologic management of excessive daytime sleepiness[J]. Sleep Med Clin, 2020, 15(2):177-194.
[2]	Ito E, Inoue Y. [The International Classification of Sleep Disorders, third edition. American Academy of Sleep Medicine. Includes bibliographies and index][J]. Nihon Rinsho, 2015, 73(6):916-923.
[3]	Suzuki K, Okuma Y, Uchiyama T, et al. Impact of sleep-related symptoms on clinical motor subtypes and disability in Parkinson's disease: a multicentre cross-sectional study[J]. J Neurol Neurosurg Psychiatry, 2017, 88(11): 953-959.
[4]	Lin YY, Chen RS, Lu CS, et al. Sleep disturbances in Taiwanese patients with Parkinson's disease[J]. Brain Behav, 2017, 7(10):e00806.
[5]	Zhu K, van Hilten JJ, Marinus J. Course and risk factors for excessive daytime sleepiness in Parkinson's disease[J]. Parkinsonism Relat Disord, 2016, 24:34-40.
[6]	Tholfsen LK, Larsen JP, Schulz J, et al. Development of excessive daytime sleepiness in early Parkinson disease[J]. Neurology, 2015, 85(2):162-168.
[7]	Yousaf T, Pagano G, Niccolini F, et al. Excessive daytime sleepiness may be associated with caudate denervation in Parkinson disease[J]. J Neurol Sci, 2018, 387:220-227.
[8]	中华医学会神经病学分会，中华医学会神经病学分会睡眠障碍学组，解放军医学科学技术委员会神经内科专业委员会睡眠障碍.中国发作性睡病诊断与治疗指南[J].中华神经科杂志，2015，48(6):445-452.
[9]	中华医学会神经病学分会帕金森病及运动障碍学组，中国医师协会神经内科医师分会帕金森病及运动障碍专业.中国帕金森病的诊断标准（2016版）[J].中华神经科杂志，2016，49(4):268-271.
[10]	Videnovic A, Klerman EB, Wang Wei, et al. Timed light therapy for sleep and daytime sleepiness associated with Parkinson disease: A randomized clinical trial[J]. JAMA Neurol, 2017, 74(4):411-418.
[11]	Albers JA, Chand P, Anch AM. Multifactorial sleep disturbance in Parkinson's disease[J]. Sleep Med, 2017, 35: 41-48.
[12]	Huang J, Zhuo W, Zhang Y, et al. Cognitive function characteristics of Parkinson's disease with sleep disorders[J]. Parkinsons Dis, 2017, 2017:4267353.
[13]	Qin X, Li X, Chen G, et al. Clinical features and correlates of poor nighttime sleepiness in patients with Parkinson's disease[J]. Parkinsons Dis, 2020, 2020:6378673.
[14]	Silvani A. Sleep disorders, nocturnal blood pressure, and cardiovascular risk: A translational perspective[J]. Auton Neurosci, 2019, 218:31-42.
[15]	Junho BT, Kummer A, Cardoso F, et al. Clinical predictors of excessive daytime sleepiness in patients with Parkinson's disease[J]. J Clin Neurol, 2018, 14(4):530-536.
[16]	Falup-Pecurariu C, Diaconu S. Sleep dysfunction in Parkinson's disease[J]. Int Rev Neurobiol, 2017, 133: 719-742.
[17]	Videnovic A, Noble C, Reid KJ, et al. Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease[J]. JAMA Neurol, 2014, 71(4):463-469.
[18]	Xiang YQ, Xu Q, Sun QY, et al. Clinical features and correlates of excessive daytime sleepiness in Parkinson's disease[J]. Front Neurol, 2019, 10: 121.
[19]	Gjerstad MD, Alves G, Maple-Grødem J. Excessive daytime sleepiness and REM sleep behavior disorders in Parkinson's disease: A narrative review on early intervention with implications to neuroprotection[J]. Front Neurol, 2018, 9: 961.
[20]	Kwon KY, Lee M, Ju H, et al. Risk factors for falls in patients with de novo Parkinson's disease: A focus on motor and non-motor symptoms[J]. J Mov Disord, 2020, 13(2):142-145.
[21]	Marinus J, Zhu K, Marras C, et al. Risk factors for non-motor symptoms in Parkinson's disease[J]. Lancet Neurol, 2018, 17(6):559-568.
[22]	Chan LG, Siang K, Yong TT, et al. The longitudinal impact of excessive daytime somnolence on motor and nonmotor symptoms of Parkinson's disease in a Southeast Asian cohort[J]. J Geriatr Psychiatry Neurol, 2019:891988719892326.
[23]	Höglund A, Hagell P, Broman JE, et al. A 10-year follow-up of excessive daytime sleepiness in Parkinson's disease[J]. Parkinsons Dis, 2019, 2019:5708515.
[24]	Yoo SW, Kim JS, Oh YS, et al. Excessive daytime sleepiness and its impact on quality of life in de novo Parkinson's disease[J]. Neurol Sci, 2019, 40(6):1151-1156.
[25]	Vecchierini MF, Kilic-Huck U, Quera-Salva MA, et al. Melatonin (MEL) and its use in neurological diseases and insomnia: Recommendations of the French Medical and Research Sleep Society (SFRMS) [J]. Rev Neurol (Paris), 2020, 177(3):245-259.
[26]	Kredlow MA, Capozzoli MC, Hearon BA, et al. The effects of physical activity on sleep: A meta-analytic review[J]. J Behav Med, 2015, 38(3):427-449.
[27]	Nascimento CM, Ayan C, Cancela JM, et al. Effect of a multimodal exercise program on sleep disturbances and instrumental activities of daily living performance on Parkinson's and Alzheimer's disease patients[J]. Geriatr Gerontol Int, 2014, 14(2):259-266.
[28]	Silva-Batista C, de Brito LC, Corcos DM, et al. Resistance training improves sleep quality in subjects with moderate Parkinson's disease[J]. J Strength Cond Res, 2017, 31(8):2270-2277.
[29]	Xiao CM, Zhuang YC. Effect of health Baduanjin Qigong for mild to moderate Parkinson's disease[J]. Geriatr Gerontol Int, 2016, 16(8):911-919.

组别	例数	年龄（岁）	性别（男/女）	病程（年）	Hoehn-Yahr分期[例（%）]				ESS
组别	例数	年龄（岁）	性别（男/女）	病程（年）	2期	2.5期	3期	4期	ESS
干预组	24	80.7±7.0	14/10	7.94±3.61	16（69.6）	4（17.4）	2（8.7）	1（4.3）	15.16±3.15
对照组	27	81.7±7.7	16/11	8.62±4.04	14（56.0）	7（28.0）	2（8.0）	2（8.0）	14.95±2.61
检验值		t=0.374	χ²=0.004	t=0.827	χ²=1.204				t=0.572
P值		>0.05	>0.05	>0.05	>0.05				>0.05
组别	例数	PDSS	PSQI	FRAIL	SAS	SDS	ADL
干预组	24	75.74±22.34	8.12±4.12	3.27±0.76	41.06±6.11	39.83±3.40	50.92±15.03
对照组	27	77.65±21.04	7.56±2.81	3.12±1.07	36.34±7.83	35.09±8.42	45.47±13.28
检验值		t=0.873	t=0.293	t=0.473	t=0.829	t=0.958	t=0.374
P值		>0.05	>0.05	>0.05	>0.05	>0.05	>0.05

组别	例数	年龄（岁）	性别（男/女）	病程（年）	Hoehn-Yahr分期[例（%）]				ESS
组别	例数	年龄（岁）	性别（男/女）	病程（年）	2期	2.5期	3期	4期	ESS
干预组	24	80.7±7.0	14/10	7.94±3.61	16（69.6）	4（17.4）	2（8.7）	1（4.3）	15.16±3.15
对照组	27	81.7±7.7	16/11	8.62±4.04	14（56.0）	7（28.0）	2（8.0）	2（8.0）	14.95±2.61
检验值		t=0.374	χ²=0.004	t=0.827	χ²=1.204				t=0.572
P值		>0.05	>0.05	>0.05	>0.05				>0.05
组别	例数	PDSS	PSQI	FRAIL	SAS	SDS	ADL
干预组	24	75.74±22.34	8.12±4.12	3.27±0.76	41.06±6.11	39.83±3.40	50.92±15.03
对照组	27	77.65±21.04	7.56±2.81	3.12±1.07	36.34±7.83	35.09±8.42	45.47±13.28
检验值		t=0.873	t=0.293	t=0.473	t=0.829	t=0.958	t=0.374
P值		>0.05	>0.05	>0.05	>0.05	>0.05	>0.05

组别	例数	ESS			PDSS
组别	例数	干预前	干预4周	干预6周	干预前	干预4周	干预6周
干预组	24	15.16±3.15	11.86±4.22	11.65±2.14	75.74±22.34	88.24±18.55	108.4.37±20.62
对照组	27	14.95±2.61	14.31±3.08	14.88±3.29	77.65±21.04	78.23±25.85	76.54±18.73
组别	例数	FRAIL			SAS
组别	例数	干预前	干预4周	干预6周	干预前	干预4周	干预6周
干预组	24	3.27±0.76	3.84±1.28	2.97±1.33	41.06±6.11	42.00±4.60	41.70±6.12
对照组	27	3.12±1.07	3.02±0.54	3.09±1.34	36.34±7.83	39.00±7.81	38.00±10.31
组别	例数	SDS			ADL
组别	例数	干预前	干预4周	干预6周	干预前	干预4周	干预6周
干预组	24	39.83±3.40	36.02±6.00	37.40±4.89	50.92±15.03	49.25±20.03	48.28±17.73
对照组	27	35.09±8.42	34.80±8.21	35.84±5.96	45.47±13.28	50.23±17.26	51.82±10.37

组别	例数	ESS			PDSS
组别	例数	干预前	干预4周	干预6周	干预前	干预4周	干预6周
干预组	24	15.16±3.15	11.86±4.22	11.65±2.14	75.74±22.34	88.24±18.55	108.4.37±20.62
对照组	27	14.95±2.61	14.31±3.08	14.88±3.29	77.65±21.04	78.23±25.85	76.54±18.73
组别	例数	FRAIL			SAS
组别	例数	干预前	干预4周	干预6周	干预前	干预4周	干预6周
干预组	24	3.27±0.76	3.84±1.28	2.97±1.33	41.06±6.11	42.00±4.60	41.70±6.12
对照组	27	3.12±1.07	3.02±0.54	3.09±1.34	36.34±7.83	39.00±7.81	38.00±10.31
组别	例数	SDS			ADL
组别	例数	干预前	干预4周	干预6周	干预前	干预4周	干预6周
干预组	24	39.83±3.40	36.02±6.00	37.40±4.89	50.92±15.03	49.25±20.03	48.28±17.73
对照组	27	35.09±8.42	34.80±8.21	35.84±5.96	45.47±13.28	50.23±17.26	51.82±10.37

组别	例数	睡眠时间（h）			潜伏期（min）
组别	例数	干预前	干预4周	干预6周	干预前	干预4周	干预6周
干预组	24	7.0±1.0	7.3±1.0	7.3±0.9	37±21	28±10	20±12
对照组	27	7.0±1.3	7.4±1.3	7.3±1.3	34±16	32±16	33±21
组别	例数	睡眠中断次数			夜间睡眠觉醒时间（min）
组别	例数	干预前	干预4周	干预6周	干预前	干预4周	干预6周
干预组	24	3.5±1.0	2.9±1.0	1.8±1.1	40.2±28.5	39.7±30.0	45.2±30.6
对照组	27	3.2±1.1	3.1±1.1	3.2±1.0	39.5±19.6	31.8±23.3	38.6±31.7
组别	例数	夜间睡眠质量评分			醒后清醒感指数
组别	例数	干预前	干预4周	干预6周	干预前	干预4周	干预6周
干预组	24	2.86±1.02	3.61±0.75	3.79±0.82	3.03±0.84	3.65±1.07	3.44±0.94
对照组	27	3.08±0.83	3.03±0.91	3.07±0.43	3.14±0.12	3.03±1.22	3.26±0.86
组别	例数	易醒评分			做梦评分
组别	例数	干预前	干预4周	干预6周	干预前	干预4周	干预6周
干预组	24	2.42±0.67	2.26±0.67	2.23±0.78	1.79±0.65	1.81±0.80	1.71±0.65
对照组	27	2.33±0.54	2.41±0.52	2.37±0.67	1.74±0.70	1.63±0.62	1.73±0.74

Please choose a citation manager

Content to export